丹蛭降糖胶囊改善2型糖尿病患者血管内皮粘附状态及炎症损伤的临床观察  

作　　者：倪英群[1] 方朝晖[1] 

机构地区：[1]安徽省中医院老年内分泌科,230031

出　　处：《中国现代药物应用》2008年第21期22-24,共3页Chinese Journal of Modern Drug Application

基　　金：国家中医药管理局中医药科学技术研究专项课题(编号:06 -07LP22);安徽省自然科学基金项目(编号:070413130);安徽省教育厅自然科学基金项目(编号:2005KJ271)

摘　　要：目的观察具有益气养阴活血功效的纯中药制剂丹蛭降糖胶囊(DJC)对2型糖尿病(T2DM)患者血管内皮粘附状态及炎症损伤的影响,探讨其延缓2型糖尿病血管并发症的机理。方法将46例2型糖尿病气虚阴亏血瘀证患者随机分为治疗组(n=24)和对照组(n=22)(2组基线水平无显著性差异),2组均常规给予西药口服降糖治疗;治疗组在此基础上,加用丹蛭降糖胶囊,2组疗程均为20周。治疗前后分别检测空腹及餐后2h血糖(PG)、血清胰岛素(INS)和胰岛素抵抗指数(IR)、可溶性血管细胞粘附分子-1(sVCAM-1)、血清超敏c反应蛋白(hs-CRP)水平。结果治疗组在应用丹蛭降糖胶囊20周后,INS、IR、sVCAM-1含量及hs-CRP水平均明显改善(P<0·05)。结论丹蛭降糖胶囊能干预2型糖尿病患者血管内皮粘附状态及炎症反应,改善内皮损伤,对于延缓2型糖尿病血管并发症有积极的意义。Objective To observe the intervention effect of danzhi jiangtang capsule （DJC） which has the efficiency of Yiqiyangyinhuoxue on Type 2 diabetes＇vascular endothelium injury induced by adhesion condition and inflammation , to approach its mechanism of delaying the occurrence of vascular complication. Methods 46 patients were randomly devided into two groups including DJC trial group （ n = 24） and western medicine control group （n = 22 ）, the two groups were treated by routine method while DJC trial group additional use DJC.The therapy lasts for 20 weeks. Detect the level of FBG, 2HPG,INS,IRI,hs-CRP,sVCAM-1 before and after the therapy. Results Compared with that of control group, the relative index improved significantly （ P 〈 0. 05） 12 weeks later, including INS,IRI,hs-CRP and sVCAM-I. Conclusion DJC can significantly improve Type 2 diabetes＇vaseular endothelium injury, delay the occurrence of vascular complication.

关 键 词：丹蛭降糖胶囊 2型糖尿病 血管内皮细胞粘附分子-1 超敏C反应蛋白 

分 类 号：R259[医药卫生—中西医结合]